Quadient Partners with Stonegate Group to Offer Convenient Parcel Pickup and Returns at 400 New Locations Across the UK
Electrolux Group publishes restated figures for the new business area structure
HOTO Pioneers Aesthetic Industrial Design in Hardware Tools, Opening New Business Opportunities in the Consumer Market
PwC Israel Collaborates with OurCrowd’s Israel Resilience Fund to Support Israel’s Tech Sector at Time of Crisis
Cielo Debuts First Generative AI for Talent Acquisition: CLO.ai
FanttikOutdoor Brings Home Away from Home with Feature-packed Camping Tents
Diagrid Improves Dapr Microservice Application Development, Launches Free Conductor Tool for Developers
Next 15 Group plc UK Regulatory Announcement: Transaction in Own Shares
PureTech Proposes $100 Million Capital Return
Traefik Labs Product Updates Set New Standard in Cloud-Native API Networking and Security
-
Elliptic Labs Chosen for Transsion’s Infinix Note 40 Series Smartphones
OSLO, Norway--(BUSINESS WIRE)--#AIVirtualProximitySensor--Elliptic Labs (OSE: ELABS), a global AI software company and the world leader in AI Virtual Smart Sensors™ currently deployed in over 500 million devices, has launched its AI Virtual Proximity Sensor™ INNER BEAUTY® on Transsion’s latest smartphone release, the Infinix Note 40 series. Transsion, the fifth largest smartphone maker globally, is releasing the Infinix Note 40 smartphone series for the global market. The Infinix Note 40 series is comprised of four smartphones: the Infinix Note 40, Note 40 Pro, Note 40 Pro 5G, and Note 40 Pro+ 5G. All four smartphones are driven by Elliptic Labs’ partner MediaTek's chipsets, with MediaTek’s Helio G99 chipset driving both the Note 40 and Note 40 Pro versions and the Dimensity 7050 chipset is at the core of the Note 40 Pro 5G and Note 40 Pro+ 5G smartphones. The contract for this launch was previously announced by Elliptic Labs. "Transsion, a top-5 global smartphone maker, is launching another four smartphones utilizing our AI Virtual Smart Sensor Platform™,” said Laila Danielsen, CEO of Elliptic Labs. “Since 2022, we have released (12) Transsion devices to market utilizing our AI Virtual Smart Sensors. In the same time, we’ve seen Transsion grow from a smaller smartphone OEM into a global Top-5 smartphone maker. The latest launch of Transsion-brand Infinix’s value-focused devices incorporating our AI Virtual Proximity Sensor, INNER BEAUTY, underscores the critical impact of our 100% software-based AI Virtual Smart Sensors. Together with Transsion and our other global customers, we are committed to bringing to market, devices that are greener, smarter, and human-friendly.” AI Virtual Proximity Sensor INNER BEAUTY Elliptic Labs’ AI Virtual Proximity Sensor detects when a user holds their phone up to their ear during a call, allowing the smartphone to turn off its display and disable its screen’s touch functionality. This keeps the user’s ear or cheek from triggering unwanted actions during the call, such as hanging up or dialing numbers. Turning off the screen also helps conserve battery life. Proximity detection is a core capability that is used in all smartphones, but Elliptic Labs’ AI Virtual Proximity Sensor is a unique, software-only solution that delivers robust proximity detection without the need for a dedicated hardware sensor. By replacing hardware sensors with software sensors, the AI Virtual Proximity Sensor reduces device cost and eliminates sourcing risk. INNER BEAUTY is a registered trademark of Elliptic Labs. AI Virtual Smart Sensor, AI Virtual Proximity Sensor, and AI Virtual Smart Sensor Platform are trademarks of Elliptic Labs. All other trademarks or service marks are the responsibility of their respective organizations. About Elliptic Labs Elliptic Labs is a global enterprise targeting the smartphone, laptop, IoT, and automotive markets. Founded in 2006 as a research spin-off from Norway’s Oslo University, the company’s patented software uses AI, ultrasound and sensor fusion to deliver intuitive 3D gesture, proximity-, presence-, breathing- and heartbeat-detection experiences. Its scalable AI Virtual Smart Sensor Platform creates software-only sensors that are sustainable, human-friendly and already deployed in hundreds of millions of devices around the world. Elliptic Labs is the only software company that has delivered detection capabilities using AI software, ultrasound, and sensor fusion deployed at scale. The company joined the Oslo Børs main listing in March 2022. Elliptic Labs is headquartered in Norway with presence in the USA, China, South Korea, Taiwan, and Japan. Its technology and IP are developed in Norway and are solely owned by the company. Contacts PR Contacts:Patrick Tsui pr@ellipticlabs.com Investor Relations:Lars Holmøy Lars.Holmoy@ellipticlabs.com
-
Innate Pharma Announces Its Participation to Upcoming Investor Conference
MARSEILLE, France--(BUSINESS WIRE)--#ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its executive team are scheduled to participate in the upcoming investor conference, detailed below. Participants will be Sonia Quaratino, Executive Vice President, Chief Medical Officer, Yannis Morel, Executive Vice President, Chief Operating Officer and Arvind Sood, Executive Vice President, President of US Operations. 2nd Annual H.C. Wainwright Cell Therapy Virtual Conference Event Date: March 26, 2024 | virtual event About Innate Pharma Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through therapeutic antibodies and its ANKET® (Antibody-based NK cell Engager Therapeutics) proprietary platform. Innate’s portfolio includes lead proprietary program lacutamab, developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, monalizumab developed with AstraZeneca in non-small cell lung cancer, as well as ANKET® multi-specific NK cell engagers to address multiple tumor types. Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients. Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US. Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X. Information about Innate Pharma shares ISIN codeTicker codeLEI FR0010331421 Euronext: IPH Nasdaq: IPHA 9695002Y8420ZB8HJE29 Disclaimer on forward-looking information and risk factors This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including “believe,” “potential,” “expect” and “will” and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s commercialization efforts and the Company’s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2022, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country. Contacts For additional information, please contact: InvestorsInnate PharmaHenry Wheeler Tel.: +33 (0)4 84 90 32 88 Henry.wheeler@innate-pharma.fr Media RelationsNewCapArthur Rouillé Tel.: +33 (0)1 44 71 00 15 innate@newcap.eu
-
AMWC 2024: Galderma to Share New Data From Its Leading Injectable Aesthetic Portfolio
Galderma’s diverse portfolio and educational efforts will be highlighted in 16 posters, and two sponsored symposia, exploring insights from the ground-breaking ‘NEXT by Galderma’ future aesthetic trends report and the use of Sculptra® for the body, as we celebrate its 25th anniversary Galderma will present pivotal clinical data on Restylane® SHAYPE™, the latest innovation complementing the Restylane portfolio, powered by the next generation of hyaluronic acid technology, NASHA HD™, which supports its safe and effective use for augmentation and correction of chin retrusion1 Results showing high patient-reported satisfaction and improved wellbeing through six months after treatment with RelabotulinumtoxinA, an investigational highly-active, innovative, complex-free, and ready-to-use liquid neuromodulator, will also be presented2,3 ZUG, Switzerland--(BUSINESS WIRE)--Galderma will present the latest updates from its broad portfolio of clinically-proven and holistic range of aesthetic treatments at the 22nd Aesthetic & Anti-Aging Medicine World Congress (AMWC) on March 27-29, 2024. The diversity of Galderma’s portfolio, designed to meet the individual needs of healthcare professionals and patients, will be showcased in 16 research posters – including data from the world’s most diverse range of fillers (Restylane®), leading neuromodulator portfolio (RelabotulinumtoxinA, Alluzience® and Azzalure®) and original biostimulator (Sculptra®) – as well as two symposia and a booth, which will host an array of live demonstrations and ‘Meet the Expert’ sessions. “Galderma’s extensive activities at AMWC demonstrate our commitment to pushing the boundaries of injectable aesthetics, to anticipate and address tomorrow’s needs today. By evolving and expanding our existing treatments, developing new innovations, and conducting cutting-edge research into the groundbreaking trends that are anticipated to drive the future of aesthetics, our future-facing approach ensures we continue to deliver the best for healthcare professionals and patients.” BALDO SCASSELLATI SFORZOLINI, M.D., Ph.D. GLOBAL HEAD OF R&D GALDERMA Educating on the future of aesthetics and Sculptra’s expanding indications The Galderma-sponsored symposium, The AART™ and Science behind NEXT, will host a panel of world-renowned aesthetic experts, including Dr. Sebastian Cotofana, Dr. Alessandra Haddad, Dr. Christoph Martschin, Dr. Andreas Nikolis, Dr. Sachin Shridharani, and Dr. Van Park, who will delve into the six identified groundbreaking trends that are anticipated to drive the future of aesthetics and how they will impact consultation and interaction with patients. A live demonstration will show how to best integrate the trends’ insights in practice via Galderma’s holistic assessment tool, the AART methodology, and create bespoke treatment plans for patients. The event is taking place in Room Prince Pierre on Wednesday March 27, 2024, from 2:00 to 4:00 PM CET. As we celebrate 25 years of science and expertise in biostimulation with Sculptra, Galderma’s second symposium, The AART™ of Sculptra beyond the face, will focus on how to use the AART assessment tool to address patients’ body concerns and needs. Prominent experts in the field, including Dr. Luiz Avelar, Dr. Sebastian Cotofana, Dr. Alessandra Haddad, and Dr. Marcus Morais, will focus on how to assess and treat the gluteal (buttock) region to address different patient profiles with Sculptra treatment. Through clinical cases, they will also touch on Sculptra’s use on the décolletage, neck and upper arms. The event is taking place in Room Van Dongen on Thursday March 28, 2024, from 11:00 to 11:55 AM CET. Extensive data spotlight how Galderma is advancing dermatology for every skin story Pivotal clinical data supporting the safe and effective use of Restylane SHAYPE™ for augmentation and correction of chin retrusion, with clinical results sustained for up to 12 months, will be presented.1 Restylane SHAYPE is the latest innovation in hyaluronic acid (HA) injectables, powered by new NASHA HD™ technology, the next generation in HA science. Restylane SHAYPE is engineered to shape angles in the lower face by providing a bone mimicking effect.1 It is the newest addition to the Restylane portfolio, the world’s most diverse range of fillers with over 27 years of clinical data, which encompasses different technologies (NASHA®, OBT™ and now NASHA HD) and gel characteristics, with solutions available to meet the needs of patients and injectors all over the world.4 Additional data from studies of Restylane VOLYME™ and EYELIGHT™ will be shared for midface augmentation and correction of infraorbital hollows (dark under-eye shadows and grooves), respectively, with improvements maintained through to 12 months.5,6 New data from the phase III READY-1 and READY-2 studies will also be presented, showing high patient-reported satisfaction and improved wellbeing through six months after treatment with RelabotulinumtoxinA for glabellar lines (frown lines) and lateral canthal lines (crow’s feet).2,3 The treatment was well tolerated and improvement in frown line and crow’s feet severity and aesthetic appearance was maintained through six months.2,3 Developed using Galderma’s proprietary PEARLTM technology, RelabotulinumtoxinA is a highly-active, ready-to-use solution that delivers fast and sustained results and maximizes ease-of-use to address the real needs of patients and healthcare professionals.7-19 Six posters on Sculptra, the first and original biostimulator, with a unique PLLA-SCA™ formulation that activates the body's natural power to revitalize key components of the skin for a more youthful appearance, will be presented at AMWC. Additional data spanning our leading neuromodulator portfolio, Alluzience and Azzalure, will be presented, as well as a new skin quality assessment scale and the AART-HIT™ approach for combining aesthetic products to maximize patient outcomes. More details on scientific presentations supported by Galderma at AMWC can be found here.* *All presenters are paid consultants or employees of Galderma. About the Restylane® Portfolio With more than 27 years of experience, over 160 clinical publications, and trusted with 65 million treatments and growing worldwide, the Restylane portfolio’s three complementary gel technologies – NASHA®, OBT™ and NASHA HD™ – allow for individualized, natural-looking results and long-term patient satisfaction.4,20,21 The uniqueness and complementary nature of the Restylane portfolio allows for individualized, natural-looking results, providing long-lasting improvement and long-term satisfaction for patients’ self-confidence.4,20-23 About RelabotulinumtoxinA (QM1114) Developed by Galderma, RelabotulinumtoxinA is a highly-active, innovative, complex-free, and ready-to-use liquid neuromodulator with a proprietary strain and manufactured using a unique state-of-the-art process. It is designed as a liquid, avoiding the traditional requirement to reconstitute from powder and eliminating variability, errors and risks associated with reconstitution, which would be expected to improve the consistency of results. RelabotulinumtoxinA is currently being investigated globally by Galderma, to expand its neuromodulator portfolio as part of the broadest Injectable Aesthetics portfolio on the market. RelabotulinumtoxinA is an investigational product and has not received approval for any indication in any country. About Sculptra® Sculptra is the original biostimulator and is clinically proven to stimulate the skin's innate collagen (type I) production to increase skin firmness and radiance, for long-lasting, natural-looking rejuvenated appearance. Sculptra is proven to increase collagen type I by 66.5% after three months through a process that starts stimulation as early as five days after injection.24 It helps progressively restore the skin’s foundation and natural structural function. Sculptra is proven to achieve natural-looking results that last for more than two years.25 Sculptra provides targeted collagen stimulation, with unique treatment protocols developed for each treatment area and to achieve the patients’ desired results. About Galderma Galderma is the emerging pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market though Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com. References 1. Nikolis, A, et al. Effectiveness and Safety of a New NASHA-HD Hyaluronic Acid Injectable, HASHA, for Augmentation and Correction of Chin Retrusion. E-poster presented at AMWC 2024 2. Gold, M, et al. Subject-Reported Improvement in Well-Being and High Satisfaction After Glabellar Line Treatment with RelabotulinumtoxinA, an Investigational ready-to-Use Liquid Botulinum Toxin (READY-1 Phase III Trial). E-poster presented at AMWC 2024 3. Grunebaum, L, et al. Improved Well-Being and Natural-Looking Results After Treatment of Lateral Canthal Lines with RelabotulinumtoxinA, an Investigational Liquid Botulinum Toxin (READY-2 Phase III Trial). E-poster presented at AMWC 2024 4. Carlo Di Gregorio. 25+ Years of Experience with the Restylane Portfolio of Injectable Hyaluronic Acid Fillers for Facial Aesthetic Treatment. E-poster presented at AMWC 2024 5. Ren, R, et al. Midface Augmentation in Chinese Subjects Using a Flexible Hyaluronic Acid Filler Evaluated in a Randomized No-treatment Controlled Study. E-poster presented at AMWC 2024 6. Biesman, B, et al. A Study Evaluating the Safety and Effectiveness of Hyaluronic Acid Filler HAEYE for Correction of Infraorbital Hollows (IOH, Tear Trough Study). E-poster presented at AMWC 2024 7. Galderma. Data on file. Clinical Study Report for Protocol 43QM1602: READY-1. Galderma Laboratories; 2021 8. Galderma. Data on file. Clinical Study Report for Protocol 43QM1901: READY-2. Galderma Laboratories; 2021 9. Galderma. Data on file. READY-2 Post-hoc Tables. Galderma Laboratories; 2021 10. Galderma. Data on file. Clinical Study Report for Protocol 43QM1902: READY-3. Galderma Laboratories; 2021 11. Galderma. Data on file. Clinical Study Report for Protocol 43AM1903: READY-4. Galderma Laboratories; 2021 12. Galderma. Data on file: Initial results of the phase IIIb 43QM2106 trial; 2023 13. Galderma. Data on file: Initial results of the phase IIIb 43QM2107 trial; 2023 14. Solish, N, et al. Treatment of Moderate-to-Severe Glabellar Lines with RelabotulinumtoxinA, an Investigational Liquid Botulinum Toxin: Clinical Efficacy and Safety Results from the READY-1 Phase III trial. Abstract presented at TOXINS 2024 15. Ablon, G, et al. Treatment of Lateral Canthal Lines with RelabotulinumtoxinA, an Investigational Liquid Botulinum Toxin: Clinical Efficacy and Safety Results from the READY-2 Phase III Trial. Abstract presented at TOXINS 2024 16. Bertucci, V, et al. Efficacy and Safety of a Novel Formulation Liquid Botulinum Toxin, RelabotulinumtoxinA, when used for Combination Treatment of Glabellar and Lateral Canthal Lines. Abstract presented at TOXINS 2024 17. Persson, C, et al. Patient and Investigator Treatment Experience with Ready-to-Use AbobotulinumtoxinA Solution Versus Powder BotulinumtoxinA for Treatment of Glabellar Lines. Abstract presented at TOXINS 2024 18. Sundberg, AL, and Stahl, U. Relabotulinum toxin - a novel, high purity BoNT-A1 in liquid formulation. Presented at: TOXINS 2021 19. Do, M, et al. Purification process of a complex-free highly purified botulinum neurotoxin type A1 (BoNT-A1) - relabotulinumtoxinA. Presented at: TOXINS 2022 20. Nikolis, A, et al. The Role of Clinical Examination in Midface Volume Correction Using Hyaluronic Acid Fillers: Should Patients Be Stratified by Skin Thickness? Aesthet Surg J Open Forum. 2020; 2(1):1–12. 21. Galderma. Data on file. Subject satisfaction (GAIS) – NASHA and OBT Fillers. 2021 22. Narins, RS, et al. Persistence of nasolabial fold correction with a hyaluronic acid dermal filler with retreatment: results of an 18-month extension study. Dermatol Surg. 2011;37:644–650 23. Talarico, S, et al. High Patient Satisfaction of a Hyaluronic Acid Filler Producing Enduring Full-Facial Volume Restoration: An 18-Month Open Multicenter Study. Dermatol Surg. 2015;41:1361–1369 24. Goldberg, D, Guana, A, Volk, A, Daro-Kaftan, E. Single-arm study for the characterization of human tissue response to injectable poly-L-lactic acid. Dermatol Surg. 2013;39(6):915-922 25. Fabi, S, et al. 24-month clinical trial data on effectiveness and safety after correction of cheek wrinkles using a biostimulatory poly-L-lactic acid injectable implant. Poster presented at AMWC 2023 Contacts For further information:Christian Marcoux, M.Sc. Chief Communications Officer christian.marcoux@galderma.com+41 76 315 26 50 Sébastien Cros Corporate Communications Director sebastien.cros@galderma.com+41 79 529 59 85 Emil Ivanov Head of Strategy, Investor Relations, and ESG emil.ivanov@galderma.com+41 21 642 78 12 Jessica Cohen Investor Relations and Strategy Director jessica.cohen@galderma.com+41 21 642 76 43
-
NATURE'S MIRACLE HOLDING INC. RECENTLY RANG THE CLOSING BELL AT NASDAQ, TIMES SQUARE NYC
NEW YORK, March 19, 2024 /PRNewswire/ -- Nature's Miracle Holding Inc. (the "Company" or "Nature's Miracle") (NASDAQ Global Market: NMHI; NASDAQ Capital Market: NMHIW) Chairman and Chief Executive Officer James Li just recently rang the closing bell at the Nasdaq Stock Market studio in Times Square, New York City. The ceremony signifies the trading of the Company stock under the symbol "NMHI" on The Nasdaq Global Market and the trading of the Company warrants under the symbol "NMHIW" on The Nasdaq Capital Market. Prior to this ceremony, Nature's Miracle successfully closed its business combination transaction with LBBB Merger Corp. on March 11, 2024. Nature's Miracle's management, its board of directors and guests joined in the Nasdaq studios to celebrate this momentous occasion. Complete video footage can be seen at https://www.nasdaq.com/videos/natures-miracle-inc-rings-the-nasdaq-stock-market-closing-bell. Management Comments Per James Li, Chairman and Chief Executive Officer of Nature's Miracle, "Nature's Miracle is thrilled and honored to join the Nasdaq family of listed companies. This is another great milestone for our Company and its subsidiaries in North America. We have come a long way to build an innovative controlled environment agricultural companies supplying equipment, controls systems and other CEA technologies and products. Our goal is to bring the best and cost-effective technology to the indoor farm operators in North American so that consumers can have access to fresh and low-cost vegetable products. Our mission is to reduce carbon emission, conserve water and promote energy efficiency for the CEA industry." About Nature's Miracle Holdings Inc. Nature's Miracle (www.Nature-Miracle.com) is a growing agriculture technology company providing equipment and services to growers in the Controlled Environment Agriculture ("CEA") industry which also includes vertical farming in North America. Nature's Miracle offers hardware to design, build and operate various indoor growing settings including greenhouse and indoor-growing spaces. Nature's Miracle, through its two wholly-owned subsidiaries (Visiontech Group, Inc. and Hydroman, Inc.), provides grow lights as well as other hydroponic products to hundreds of indoor growers in North America. Important Information About Press Release This press release includes information about a bell ringing ceremony. This occurred on March 14, 2024 at the Nasdaq Market studios in New York City. More information can be obtained on Nasdaq.com This press release contains the chairman's comments on the listing of Nature's Miracle. Such comments are not construed to imply immediate and assured access to the capital markets, whether in the form of debt or equity capital. Such comments are not construed to imply growth of revenue and market share as a result of visibility of the Nasdaq ceremonies and this press release(s) and does not construe increased abilities to obtain supplier and business partnerships as a result of this announcement. This press release contains references to clearance and approvals from the Securities and Exchange Commission (SEC), the closing of the business combination transaction involving Nature's Miracle and Lakeshore Acquisition II. A full description of the terms of the business combination have been provided in a Registration Statement on Form S-4 and subsequent SEC filings. The SEC filings can be obtained on sec.gov or by writing directly to Nature's Miracle Holding Inc., 858 N. Central Ave., Upland, CA 91786. This press release does not contain all the information that should be considered concerning the stock of Nature's Miracle, its warrants, and its related businesses. The press release is not intended to form the basis of any investment decision or any other decision in respect to the listing on Nasdaq, or approval by the SEC. Forward-looking Statements Except for historical information contained herein, this press release contains certain "forward-looking statements" within the meaning of the federal U.S. securities laws with respect to the Nasdaq listing and business of Nature's Miracle; other future references such as the benefits of the Nasdaq listing and SEC approval, the amount and potential funding of new capital, the services and markets of Nature's Miracle, our expectations regarding future growth, results of operations, performance, future capital and other expenditures, competitive advantages, business prospects and opportunities, future plans and intentions, results, level of activities, performance, goals or achievements or other future events. These forward-looking statements generally are identified by words such as "anticipate," "believe," "expect," "may," "could," "will," "potential," "intend," "estimate," "should," "plan," "predict," or the negative or other variations of such statements, reflect our management's current beliefs and assumptions and are based on the information currently available to our management. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual results or developments to differ materially from those expressed or implied by such forward-looking statements, including but not limited to: (i) the risk that the business and revenue prospects of Nature's Miracle may not materialize which may adversely affect the price of Nature Miracle's securities; (ii) the listing is not a conventional initial public offering, no sale of stock and immediate cash infusion occurs for the Company; the Company can continue facing the risk that the capital markets may not provide capital or liquidity options whether in the form of issuing equity or debt instruments; (iii) the failure to fulfill debt obligations due to service providers related to the listing and SEC approval since the application was submitted in late 2022l (iv) the occurrence of any unforeseen event that would impact continued listing on the Nasdaq exchange; (v) the effect of the announcement or visibility of the Nasdaq listing on Nature's Miracle's business relationships, operating results and business generally; (vi) risks that new debt levels and capitalization of the merged Company poses continued risks and potentially influence its abilities to secure additional debt or bank financing; (vii) the outcome of any legal proceedings that may be instituted against Nature's Miracle or the listing of its securities; (viii) the ability to maintain the listing of Nature's Miracle's securities on The Nasdaq Global Market and The Nasdaq Capital Market, as applicable; (ix) changes in the competitive industries in which Nature's Miracle operates, variations in operating performance across competitors, changes in laws and regulations affecting Nature's Miracle's business and changes in the combined capital structure; (x) the ability to implement business plans, forecasts and other expectations after the completion of the proposed transaction, and identify and realize additional opportunities; (xi) the risk of downturns in the market and Nature's Miracle's industry including, but not limited to market prices of indoor grower's produce, transportation costs, competition with outdoor growers and demand in the consumer marketplace ; (xii) costs related to the transaction and the failure to realize anticipated benefits of the transaction or to realize estimated pro forma results and underlying assumptions, including with respect to estimated stockholder redemptions; (xiii) risks and uncertainties related to Nature's Miracle's business, including, but not limited to risks relating to the uncertainty of the projected financial information with respect to Nature's Miracle risks relating to Nature's Miracle's being unable to renew the leases of their facilities and warehouses; Nature's Miracle's ability to grow the size of its organization and management in response of the increase of sales and marketing infrastructure; risks relating to potential tariffs or a global trade war that could increase the cost of Nature's Miracle's products; risks relating to product liability lawsuits that could be brought against Nature's Miracle;; Nature's Miracle's ability to formulate, implement and modify as necessary effective sales, marketing, and strategic initiatives to drive revenue growth; Nature's Miracle's ability to expand internationally; acceptance by the marketplace of the products and services that Nature's Miracle markets; and government regulations and Nature's Miracle's ability to obtain applicable regulatory approvals and comply with government regulations. The foregoing list of factors is not exclusive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of proxy statement, when available, and other documents filed by Nature's Miracle from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date on which they are made, and neither Nature's Miracle assume any obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements. Nature's Miracle does not give any assurance that the Company will achieve its expectations. Non-solicitation This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential business combination or any other matter and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of Nature's Miracle, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended.
-
Ubitus Unleashes Generative AI and Cloud Gaming Synergies in Asia with Investment from NVIDIA
TOKYO, March 19, 2024 /PRNewswire/ -- Ubitus K.K. (hereinafter Ubitus), a leading provider of cloud gaming technology and solutions, announced today that it has received new investment funding from NVIDIA. This announcement underscores the immense potential and accelerating demand for generative AI and cloud gaming across Asia and beyond. Pioneering Cloud Gaming Wide Adoption Ubitus has been at the helm of cloud gaming, breaking down entry barriers and offering gamers worldwide access to high-quality games without the need for high-end hardware. Ubitus' success is established on its expertise in managing high-computational applications in the cloud, delivering device-agnostic user experiences through native apps or browsers, managing one of Asia's largest GPU farms, and its ability to quickly adopt the latest technologies for customized solutions. These core competencies shall be equally instrumental in future generative AI and cloud gaming growth. Synergizing Generative AI and Cloud Gaming Ubitus has been collaborating with NVIDIA to build out its GPU cloud infrastructure. Prior to this investment, Ubitus was already a pioneer driving the adoption of generative AI solutions for customers across various industries, including gaming, media, entertainment and retail, based on key localized foundational models. The company's portfolio includes: UbiGPT: A bespoke, gaming-centric large language model (LLM) that powers a new era of interactive storytelling and game development, enabling games to offer unparalleled narrative depth and dynamic player engagement. UbiArt: An advanced graphic and video diffusion service that leverages AI to transform game visuals into stunning, lifelike art, elevating the aesthetic experience for gamers and creators alike. Ubi-chan: An innovative AI avatar platform, tailor-made for gamers and creators, offering personalized, interactive avatars that enhance online presence and community engagement. With support from NVIDIA's accelerated computing, Ubitus expects to further advance its solution offerings to customers. Promising Future Growth Ubitus' investment funding represents a pivotal moment in the advancement of generative AI and cloud gaming in Asia. By leveraging the strengths of NVIDIA, Ubitus is set to unlock new possibilities for AI creation, distribution, and consumption. As the company stands on the brink of a new AI dawn, the impact of its work will resonate across industries, geographies, and cultures, reshaping the digital landscape for future generations. About Ubitus Ubitus K.K. is a technology leader specializing in GPU virtualization, cloud solutions, and streaming platform. Our focus is on delivering exceptional cloud and AI services and values to customers. Leveraging the power of GPUs, Ubitus has developed a broad range of AI solutions, including UbiGPT (Taiwan LLM), Ubi Anchor (AI anchor), Ubi-chan (AI avatar), and UbiArt (image and video generation software). Ubitus is committed to delivering tailor-made solutions designed to meet the diverse requirements of customers in various industries. Ubitus' cloud gaming solution enables users to enjoy AAA gaming experiences across devices. Through our comprehensive Game Development Kit (GDK) and game library, we offer a one -stop solution and rapid deployment, catering towards international clients that are interested in cloud gaming. For Metaverse applications, Ubitus possesses extensive global cloud deployment resources to stream interactive media content for platform operators and digital content developers.
-
Takeda Hospital Group Joins TriNetX Network to Revolutionize Medical Care in Japan
CAMBRIDGE, Mass., March 19, 2024 /PRNewswire/ -- Takeda Hospital Group, a leading healthcare provider in Kyoto, Japan Prefecture, has joined the TriNetX, LLC (TriNetX) network. Recognizing the need for tailored treatments based on the distinct genetic and lifestyle factors of Japanese patients, Takeda Hospital Group will leverage the TriNetX Network to support clinical research trials. Jun Takeda, Director of Koseikai Takeda Hospital, expressed enthusiasm about the partnership, stating, "With the constant introduction of new drugs, we expect to highlight the potential risks and benefits of various drug combinations across medical departments by using TriNetX's large-scale data for research such as age-specific analytical research." Shogo Wakabayashi, Japan Country Manager at TriNetX, welcomed Takeda Hospital Group into their network, saying," We are delighted to welcome the Takeda Hospital Group to the TriNetX Network of healthcare organizations. With our expanding presence in the APAC region and Japan, we are confident in our ability to assist Takeda Hospital Group in achieving their goals." Takeda Hospital Group provides a wide range of services in Kyoto Prefecture, including eight advanced medical care hospitals (1,592 beds) ranging from highly acute to chronic care, and more than 70 medical, health checkup, home, nursing care, and welfare programs. Chairman of the Takeda Hospital Group, Takahisa Takeda, highlighted the significance of the partnership in navigating the complexity of modern medical care. He remarked, "In today's increasingly intricate medical landscape, collaborating with TriNetX will enable us to visualize clinical data, share knowledge among medical professionals, and benefit patients, healthcare providers, and society by reducing drug loss and lag, particularly for drugs already approved outside of Japan." About TriNetX, LLCTriNetX is a global network of healthcare organizations and life sciences companies driving real-world research to accelerate the development of new therapies. Through its self-service, HIPAA, GDPR, and LGPD-compliant platform of federated EHR, datasets, and consulting partnerships, TriNetX puts the power of real-world data into the hands of its worldwide community to improve protocol design, streamline trial operations, refine safety signals, and enrich real-world evidence generation. For more information, visit TriNetX at www.trinetx.com Media Contact TriNetXMichelle Fleming+1-857-285-6038Michelle.Fleming@TriNetX.comjapan@trinetx.com Media Contact Takeda Hospital Group+81-75-353-3838
-
MCE 2024 Milan: Midea RAC Unveils Sustainable Solutions for Cooling, Heating, and Domestic Hot Water Needs
MILAN, March 19, 2024 /PRNewswire/ -- Under the inspiring theme of "GREEN VISION BLUE FUTURE," Midea, a global frontrunner in air conditioning solutions, made a significant impact at the Mostra Convegno Expocomfort (MCE) 2024 in Milan. This esteemed event is a focal point for professionals in HVAC (Heating, Ventilation, Air Conditioning), plumbing, and renewable energy sectors. Midea's Residential Air Conditioner Division (Midea RAC) took center stage, unveiling an array of products and solutions that captured the essence of innovation. The showcase featured the R290 products, the CirQHP family, and the PortaSplit, each designed to meet a wide range of needs while embodying a commitment to a sustainable future. Having achieved a remarkable global sales milestone of over 6.2 million units, Midea leads the charge in promoting their advanced R290 products, demonstrating an unwavering dedication to sustainability. At this exhibition, Midea introduced its R290 Combo product lineup and R290 multi-split research project for the first time. Midea has always been exploring the technical difficulties of the R290 one drive three multi-split system and has made initial progress in the refrigerant leakage sensor. These introductions mark Midea's commitment to providing reliable and safe products to its customers while also contributing to environmental sustainability efforts. Furthermore, Midea's focus extends to catering to diverse climates, particularly in the European market. The CirQHP family makes an all-in-one heat pump solution for cooling, heating, and domestic hot water needs a reality. Engineered for versatility, the innovative system offers a range of customizable options, including the Heat Recovery Solution, Multi-Hybrid Solution, and Indoor-Hybrid Solution. Each option is designed to provide unparalleled flexibility and convenience, ensuring each household enjoys optimal efficiency and supreme comfort. By opting for the CirQHP family, individuals are not merely selecting a product; they are embracing an intelligent, energy-efficient solution that ensures their home remains perfectly comfortable throughout the year. Additionally, Midea showcased the All-In-One Smart Energy Management System MHELIOS, epitomizing the fusion of technology and sustainability. This intelligent system, featuring a hybrid inverter, is designed to optimize the use of green electricity when integrated with solar panels, energy storage, and smart home appliances. This holistic approach to energy management aligns with Midea's Green Strategy, aiming for a sustainable future. The spotlight was also on PortaSplit, a product renowned for its creativity, which has recently garnered significant attention in the design and innovation sector. PortaSplit has attracted widespread attention due to its outstanding product performance and easy installation features. Stefan Anderi, Vice Chairman of the German Design Council, personally presented the "German Design Award" to PortaSplit. Following this achievement, PortaSplit once again showcased its ingenuity by receiving the prestigious iF Product Design Award, further solidifying its reputation for exceptional design and performance. The consecutive accolades received by PortaSplit are a testament to its innovative design. It represents an integrated new design that merges the advantages of both conventional portable air conditioners (ACs) and fixed installed split ACs. Addressing the market's demand for both energy-saving and temperature comfort solutions, PortaSplit stands out for its ability to meet consumer expectations for a superior product that resolves common issues associated with conventional ACs. It sets a new standard in the air conditioning market, promising to meet and exceed consumer expectations for a product that balances comfort with sustainability. The array of innovative products showcased by Midea RAC at MCE 2024 encapsulates the theme "GREEN VISION BLUE FUTURE." Midea RAC's passion for sustainable development is evident in a steadfast commitment to crafting cutting-edge products and solutions that elevate quality of life while safeguarding the planet. jwplayer.key="3Fznr2BGJZtpwZmA+81lm048ks6+0NjLXyDdsO2YkfE=" jwplayer('myplayer1').setup({file: 'https://mma.prnasia.com/media2/2364177/15s_V2.mp4', image: 'https://mma.prnasia.com/media2/2364177/15s_V2.mp4?p=medium', autostart:'false', stretching : 'uniform', width: '512', height: '288'});
-
SSR MINING SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead
NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 17, 2024 to file lead plaintiff applications in a securities class action lawsuit against SSR Mining Inc. (NasdaqGS: SSRM), if they purchased the Company’s securities between February 23, 2022 and February 27, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Colorado. What You May Do If you purchased securities of SSR and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgs-ssrm/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by May 17, 2024. About the Lawsuit SSR and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the Company materially overstated its commitment to safety and the efficacy of its safety measures; (ii) it engaged in unsafe mining practices which were reasonably likely to result in a mining disaster; and (iii) as a result of the foregoing, the Company’s statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times. The case is Akhras v. SSR Mining Inc., et al., 24-cv-739. About Kahn Swick & Foti, LLC KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana and New Jersey. To learn more about KSF, you may visit www.ksfcounsel.com. Contacts Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner lewis.kahn@ksfcounsel.com1-877-515-1850
-
Breakthrough in Treatment of Cervical High-Grade Squamous Intraepithelial Lesion: Release of Positive Results from Multicenter Phase III Global Clinic
The world's first non-surgical cervical HSIL treatment validated by an international Phase III clinical study with proven efficacy; The response rate increased by 89.4% compared to the placebo control group, with a low incidence of adverse events; The China new drug application submission is expected in Q2 2024, while ex-China product development is in active progress. SHANGHAI, March 19, 2024 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharmaceutical leader in the discovery, development, and commercialization of innovative drugs for genitourinary tumors and related diseases announced that the multicenter Phase III global clinical study data of its non-surgical treatment for cervical HSIL product APL-1702 demonstrated significant efficacy and good safety profile, with new advancements in clearance rate of high-risk HPV16 and/or HPV18. Key data from the study were presented in oral presentations at the 2024 European Research Organization on Genital Infection and Neoplasia (EUROGIN) Congress and the 2024 Society of Gynecologic Oncology (SGO) Annual Meeting. APL-1702 is a pioneering cold light photodynamic drug-device combination product, used as a non-surgical therapy for treating cervical HSIL. This study is a prospective, randomized, double-blinded, placebo-controlled multicenter Phase III global clinical study designed to evaluate the efficacy and safety of APL-1702 for the treatment of cervical HSIL. Primary endpoint of the study is the proportion of responders at 6 months after the initial treatment. The study is led by Dr. Jinghe Lang, an academician at Peking Union Medical College Hospital, Chinese Academy of Medical Sciences. Response is defined as the conversion of cervical epithelial tissue pathology to normal or the conversion to low-grade squamous intraepithelial lesion (LSIL) while achieving baseline HPV clearance. According to the study results, between November 2020 and July 2022, a total of 402 eligible patients from various countries including China, Germany, the Netherlands et al. were randomized and enrolled in this study. The response rate in the APL-1702 treatment group showed a statistically significant improvement of 89.4% (41.1% vs. 21.7%, p = 0.0001) compared to that in the placebo control group, indicating a remarkable therapeutic effect. Additionally, APL-1702 showed an improved clearance rate of high-risk HPV16 and/or HPV18, with a 103.9% increase in the APL-1702 treatment group compared to the control group (31.4% vs. 15.4%)[1]. The incidence of treatment-emergent adverse events (TEAEs) was comparable between the treatment group and the control group, with the majority being mild and self-healing without requiring intervention. The occurrence rates of treatment-related adverse events (TRAEs) and serious adverse events (SAEs) were both low in both groups[2]. According to the "Global Cancer Statistics 2020" report, there were 604,127 new cases of cervical cancer in women worldwide in 2020, with 341,831 deaths, ranking it as the fourth most common cancer among women. Cervical cancer incidence ranks second among malignant tumors in Chinese women. According to the "National Cancer Report 2024" released by the National Cancer Center, there were 150,700 new cases of cervical cancer in China in 2022, with 55,700 deaths from cervical cancer. The main cause of cervical cancer is persistent infection with human papillomavirus (HPV), which leads to precancerous lesions of the cervix. Approximately 25% of individuals with HSIL may progress to invasive cervical cancer within 10 years[3]. According to Frost Sullivan analysis, it is projected that by 2030, the number of HSIL patients worldwide and in China will reach 16.6 million and 2.2 million, respectively. With the increasing popularity of dual-cancer screening and cervical cytology tests, more and more patients with cervical precancerous lesions are being detected at early stages before cancer develops, and it is expected that the number of patients will continue to increase. Women with cervical precancerous lesions have unmet clinical needs for non-surgical therapies. Currently, invasive procedures such as loop electrosurgical excision procedure (LEEP) and cold knife conization remain the primary treatment options for high-grade cervical lesions. However, these surgical treatments are associated with adverse reactions including bleeding, infection, and cervical structural damage, which may lead to complications such as preterm birth and miscarriage. Furthermore, cervical precancerous lesions require long-term monitoring and management because even after surgical treatment, there is a risk of persistent disease or recurrence, with a higher risk of developing cervical cancer compared to the general population (5 times higher risk of invasive cancer within 10 years). Therefore, post-operative follow-up for at least 25 years is necessary. Importantly, if cervical precancerous lesions recur, subsequent surgical interventions become more challenging and carry higher risks, potentially resulting in total hysterectomy. Thus, early surgical intervention increases the difficulty of long-term management. Non-surgical therapies that preserve the intact cervix and avoid or delay cervical trauma are of significant importance for the long-term management of patients with cervical precancerous lesions. Professor Chen Fei, Chief Physician of the Department of Obstetrics and Gynecology at Peking Union Medical College Hospital, expressed her delight with the research findings, stating, "I am extremely pleased with the results of this study. Treating HSIL serves as the final barrier against cervical cancer. Previous international studies on HSIL have not been successful, but this study, utilizing a multicenter trial design and strict definition of efficacy endpoints, has achieved positive results, which is no easy feat. As a clinician, I have encountered many HSIL patients who desire to preserve their intact cervix while receiving treatment. The emergence of APL-1702 will fulfill the wishes of these patients, allowing them to avoid or delay cervical trauma to the maximum extent possible." Professor Qiao Youlin, a member of the WHO Global Expert Group for Cervical Cancer Elimination and a professor at the School of Population Medicine and Public Health at the Chinese Academy of Medical Sciences/Peking Union Medical College, believes that in addition to vaccination and screening, treatment of cervical precancerous lesions is a crucial component of secondary prevention for cervical cancer. However, progress in the field of medication for cervical precancerous lesions has been relatively slow, with high barriers to overcome, and there are currently no approved treatment drugs worldwide. "It is gratifying to see the emergence of innovative products like APL-1702, which simultaneously possess clinical value in addressing the treatment gap, public health value in cervical cancer prevention and control, and social value in promoting fertility-friendly options. This breakthrough will safeguard women's health and make a positive contribution to the acceleration of the 2030 global and Chinese action plans for cervical cancer elimination". Dr. Linda Wu, Chief Development Officer of Asieris Pharmaceuticals, said, "We are extremely proud of the results from the international multicenter Phase III clinical study of APL-1702. The study not only demonstrates remarkable efficacy but also exhibits a favorable safety profile, offering a new powerful artillery for the national cervical cancer prevention and control system. We express our gratitude to all the patients, physicians, and researchers who participated in this study, as their support and dedication have been invaluable. We are actively preparing the new drug application for APL-1702 and plan to submit it in the second quarter of this year. Additionally, we are making significant progress in product development overseas, aiming to bring this innovative treatment to more patients as soon as possible." References: EUROGIN: Photodynamic therapy with APL-1702 for high-grade squamous intraepithelial lesions (HSIL): results from a randomized phase Ⅲ global study (YHGT-CEV-1/APRICITY) SGO: APL-1702 long-term efficacy and safety for cervical histologic high-grade squamous intraepithelial lesions (HSIL): results from a randomized phase Ⅲ global study Gao Shujun, Sui Long. Standardized management and follow-up of high-grade squamous intraepithelial lesions of the cervix[J]. Chinese Journal of Practical Gynecology and Obstetrics. 2020,36(07):604-608. About APL-1702(Cevira®) APL-1702(Cevira®) is a breakthrough photodynamic drug-device combination product that is being developed for non-surgical treatment of high-grade precancerous lesions of the cervix. Cevira® holds the potential to serve the high unmet medical need for non-invasive treatment options for patients with HSIL in an outpatient setting, especially for young women of reproductive age. Asieris Pharmaceuticals entered into a license agreement with Photocure ASA (Photocure, PHO: OSE) to obtain the worldwide development and commercialization of Cevira® in July 2019. Cevira® is a registered trademark of Photocure ASA, based in Oslo, Norway. About Asieris Asieris Pharmaceuticals(688176.SH), founded in March 2010, is a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases. We strive to improve human health to preserve patient's dignity. We aim to become a global pharma leader that integrates R&D, manufacturing and commercialization in our areas of focus, as we provide best-in-class integrated diagnosis and treatment solutions for patients in China and worldwide. The company has been developing its proprietary R&D platform and core technologies, exploring new mechanisms of action, and efficiently screening and evaluating drug candidates. With a well-established in-house R&D system and expertise in global drug development, Asieris is committed to launching first-in-class drugs and other innovative products to address huge unmet needs in its areas of focus. Asieris is also enhancing its pipeline for genitourinary diseases via proprietary R&D and strategic partnerships, while closely following cutting-edge technologies and therapeutics. The company strives to discover and identify unmet clinical needs, and adopts a forward-looking approach in product planning and life-cycle management. We aim to establish an outstanding portfolio that covers diagnosis and treatment in a bid to benefit more patients in China and globally.
-
TAOKE ENERGY And CATL Reached A 350 MWh Battery Purchase Agreement Based On In-depth Cooperative Partnership
TOKYO, March 19, 2024 /PRNewswire/ -- During the recently concluded 2024 World Smart Energy Week exhibition held at Tokyo Big Sight in Japan, TAOKE ENERGY signed a significant 350 MWh battery purchase agreement with Contemporary Amperex Technology Co., Limited (CATL, a global leader of new energy innovative technologies). This agreement signifies a deepening of cooperation between the two companies in jointly expanding the Japanese new energy market. On Mar 1st, TAOKE ENERGY And CATL Reached A 350 MWh Battery Purchase Agreement The collaboration between TAOKE ENERGY and CATL traces back to 2018 within the residential ESS sector. Following years of successful partnership, the cooperative scope has expanded to encompass C&I and grid-scale ESS projects. As CATL's inaugural after-sales service site and strategic partner in Japan, TAOKE ENERGY is uniquely positioned to deliver efficient and secure new energy solutions to customers and can ensure optimal performance and reliability by combining the strengths of technological capabilities and the high-quality LFP BESS products manufactured by CATL. The execution of this long-term battery procurement agreement signifies a milestone in the cooperation between TAOKE ENERGY and CATL. And for TAOKE ENERGY, it represents a pivotal component of its marketing development strategies. It is anticipated that moving forward, the two entities will synergize strengths in new energy innovation technologies, reliable delivery capacity, extensive market development experience and localized service capabilities to pursue an increased market share in Japan. Consulting Information:Taoke Energy co., ltdPostal Code:105-0012Adress: 105-0012 Komatsu building 3F,Shibadaimon1-11-4,Minato-ku, Tokyo, JapanTel.: 03-6452-8666Email: Jane, sales@taoke-energy.comHP: https://www.taoke-energy.com/
-
TAOKE ENERGY And CATL Reached A 350 MWh Battery Purchase Agreement Based On In-depth Cooperative Partnership
TOKYO, March 19, 2024 /PRNewswire/ -- During the recently concluded 2024 World Smart Energy Week exhibition held at Tokyo Big Sight in Japan, TAOKE ENERGY signed a significant 350 MWh battery purchase agreement with Contemporary Amperex Technology Co., Limited (CATL, a global leader of new energy innovative technologies). This agreement signifies a deepening of cooperation between the two companies in jointly expanding the Japanese new energy market. The collaboration between TAOKE ENERGY and CATL traces back to 2018 within the residential ESS sector. Following years of successful partnership, the cooperative scope has expanded to encompass C&I and grid-scale ESS projects. As CATL's inaugural after-sales service site and strategic partner in Japan, TAOKE ENERGY is uniquely positioned to deliver efficient and secure new energy solutions to customers and can ensure optimal performance and reliability by combining the strengths of technological capabilities and the high-quality LFP BESS products manufactured by CATL. The execution of this long-term battery procurement agreement signifies a milestone in the cooperation between TAOKE ENERGY and CATL. And for TAOKE ENERGY, it represents a pivotal component of its marketing development strategies. It is anticipated that moving forward, the two entities will synergize strengths in new energy innovation technologies, reliable delivery capacity, extensive market development experience and localized service capabilities to pursue an increased market share in Japan. Consulting Information:Taoke Energy co., ltdPostal Code:105-0012Adress: 105-0012 Komatsu building 3F,Shibadaimon1-11-4,Minato-ku, Tokyo, JapanTel.: 03-6452-8666Email: Jane, sales@taoke-energy.comHP: https://www.taoke-energy.com/
-
Toshiba Receives Order for Power Generation Equipment for Renovation of Geothermal Power Plant in Kenya
~ Toshiba's high-performance turbines and generators have improved power generation output by 40% compared to conventional models ~ KAWASAKI, Japan, March 19, 2024 /PRNewswire/ -- Toshiba Energy Systems & Solutions Corporation (Toshiba ESS) announced today that it has received an order from SEPCOIII Electric Power Construction Co., Ltd. for steam turbines and generators for the geothermal power plant equipment renovation of Units 1 through 3 at the old 45MW Olkaria I geothermal power plant in Kenya. The steam turbines and generators will be shipped to the site by December 2025. Olkaria I geothermal power plant is the oldest geothermal power plant in Kenya and has been in commercial operation by the Kenya Electricity Generating Company PLC (hereinafter "KenGen") since 1981. Units 1 through 3 of the plant need renovation due to aging, and Toshiba ESS's steam turbines and generators have been selected for the renovation. This will increase the power output of Units 1 through 3 from the current 15 Megawatts(MW)to 21 MW each, enabling them to achieve a higher output with less steam. These points were highly evaluated by KenGen and led to the adoption of the contract. Kenya's economic growth is spurring demand for power. The government has responded with a comprehensive blueprint for development, Vision 2030, which currently includes provision for boosting Kenya's electricity generating capacity from renewable sources and seeking to transition to 100% green energy by 2030. Many new geothermal power plants are planned to tap into the 9GW geothermal potential in Kenya's Great Rift Valley region. Toshiba ESS and KenGen concluded a memorandum of understanding (MOU) to anticipate partnership on Operation and Maintenance (O&M) services through a combination of KenGen and Toshiba ESS's know-how and networks in 2022. They aim to provide O&M services for geothermal power plants for developing countries including East African countries outside Kenya. Toshiba ESS has several successful delivery records providing geothermal power generation systems in Kenya and other East African countries. Additionally, Toshiba ESS has contributed to the promotion of geothermal power generation by signing MOU's on geothermal power plant business with several partners in other East African nations. Shinya Fujitsuka, Director and Vice President of the Power Systems Division at Toshiba ESS, said, "I'm pleased that we can contribute to energy stability in Kenya by providing our equipment and services. Toshiba ESS will continue to provide optimal products and solutions to meet customer needs through its lineup of small to large geothermal steam turbines and generators with power outputs ranging from 1 MW to 200 MW. Aiming for the further clean energy indispensable for the realization of a sustainable society, we will contribute to the realization of a carbon neutral society by providing geothermal power plant services both in Japan and overseas." Project Overview Plant: Olkaria I geothermal power plantOwner: Kenya Electricity Generating Company PLC (KenGen)EPC* contractor: SEPCOIII Electric Power Construction Co., Ltd.Our scope of supply: Steam Turbines and Generators for Units 1 through 3, total 3 sets Photo of Olkaria I geothermal power plant *: EPC: Engineering Procurement and Construction
-
Mitsubishi Electric Named to CDP Supplier Engagement Leader
Fourth consecutive selection and seventh overall for climate-change collaboration with suppliersTOKYO--(BUSINESS WIRE)--Mitsubishi Electric Corporation (TOKYO: 6503) announced today that its environmental efforts related to supply chains have earned the company designation as a 2023 “Supplier Engagement Leader,” the highest ranking in the CDP Supplier Engagement Rating program operated by CDP, an international non-profit organization that supports environmental disclosure. This is the fourth consecutive year since 2020 and seventh time in which Mitsubishi Electric has earned a top ranking for excellent actions and strategies to reduce greenhouse gas emissions and climate-change risks throughout its supply chain. The Supplier Engagement Rating evaluates how effectively companies engage their suppliers on climate change. Companies that receive top appraisals are named a “Supplier Engagement Leader.” This year, Mitsubishi Electric has been also awarded CDP’s highest “A List” ranking for Climate Change and Water Security activities. Mitsubishi Electric, which has positioned sustainability as a cornerstone of its business, management philosophy and the company’s environmental vision 2050, aims to achieve net-zero greenhouse gas (GHG) emissions at its factories and offices by the fiscal year ending March 31, 2031 and throughout its entire value chain by the fiscal year ending March 31, 2051. Mitsubishi Electric will continue to contribute to realization of sustainable global environment throughout the global value chains, energy-saving products and systems, and cutting-edge infrastructure. For the full text, please visit: www.MitsubishiElectric.com/news/ Contacts Customer InquiriesCorporate Environmental Sustainability Dept. Mitsubishi Electric Corporation eqd.eco@pj.mitsubishielectric.co.jpwww.MitsubishiElectric.com/en/sustainability/environment/ Media InquiriesTakeyoshi Komatsu Public Relations Division Mitsubishi Electric Corporation Tel: +81-3-3218-2346 prd.gnews@nk.MitsubishiElectric.co.jpwww.MitsubishiElectric.com/news/
-
Toshiba Adds New Position Estimation Control Technology to Its Motor Control Software Development Kit to Simplify Field Oriented Control of Motors
- Now offering "MCU Motor Studio Ver.3.0" and new "Motor Parameter Tuning Tool"-KAWASAKI, Japan--(BUSINESS WIRE)--Toshiba Electronic Devices & Storage Corporation ("Toshiba") has refined motor control capabilities with the launch of two innovative tools. A new position estimation control technology for field-oriented control (FOC) has been added to the latest version of its motor control software development kit, “MCU Motor Studio Ver.3.0,” while “Motor Tuning Studio Ver.1.0” automatically calculates motor parameters. Both are available from today. FOC is a highly efficient motor control method, but difficult to realize because of the complexities of using proportional-integral (PI) control gain for tuning the motor driver. PI control is usually applied to position control, speed control and current control, producing three PI control gain parameters that interfere with each other. Adjustments can only be done through trial and error. Meanwhile, MCU Motor Studio performs motor control using known motor parameters, but the problem here is that there was no function for extracting the parameter from the motor. Toshiba’s new position estimation control method is based on a flux observer and does not use PI control for position estimation, making adjustment easier during motor evaluation. This new approach realizes greater stability during high-load operation than the conventional position estimation control. MCU Motor Studio Ver.3.0 incorporating the new method also supports the conventional position control method. The combination of MCU Motor Studio and MCU Motor Tuning Studio gives users the ability to easily derive initial motor parameters and begin evaluation. Motor Tuning Studio will be provided via Toshiba's Customer Inquiry Form here (Contact). Toshiba is advancing the realization of carbon neutrality and a circular economy, and will continue to expand its line-up of microcontrollers for FOC and motor control software development kits, and to support highly efficient motors. Follow the link below for more on MCU Motor Studio MCU Motor Studio Follow the link below for more on Toshiba’s Microcontrollers. Microcontrollers * TXZ+™ is a trademark of Toshiba Electronic Devices & Storage Corporation. * Other company names, product names, and service names may be trademarks of their respective companies. * Information in this document, including product prices and specifications, content of services and contact information, is current on the date of the announcement but is subject to change without prior notice. About Toshiba Electronic Devices & Storage Corporation Toshiba Electronic Devices & Storage Corporation, a leading supplier of advanced semiconductor and storage solutions, draws on over half a century of experience and innovation to offer customers and business partners outstanding discrete semiconductors, system LSIs and HDD products. The company's 21,500 employees around the world share a determination to maximize product value, and promote close collaboration with customers in the co-creation of value and new markets. With annual sales approaching 800-billion yen (US$6.1 billion), Toshiba Electronic Devices & Storage Corporation looks forward to building and to contributing to a better future for people everywhere. Find out more at https://toshiba.semicon-storage.com/ap-en/top.html Contacts Customer Inquiries:MCU & Digital Device Sales & Marketing Dept. Tel: +81-44-548-2233 Contact Us Media Inquiries:Chiaki Nagasawa Digital Marketing Dept. Toshiba Electronic Devices & Storage Corporation semicon-NR-mailbox@ml.toshiba.co.jp
-
New ASEAN Energy and ACTUAL Sign Cooperation Agreement to Develop Net-Zero Plan for the New $5B USD Pengerang Energy Complex
Pengerang Energy Complex has signed over $102B USD off-take agreements with several blue-chip energy providers, including Equinor, Chevron, PTT, and Mitsui. It is anticipated to have higher margins and a materially lower environmental footprint than similar plants. The Agreement between New ASEAN Energy and ACTUAL focuses on building a scientifically and technologically credible net-zero investment plan leveraging ACTUAL’s AI-driven capital planning technology. The plan seeks to improve PEC's environmental performance further to move it toward net zero. SAN FRANCISCO--(BUSINESS WIRE)--New ASEAN Energy (NAE) and ACTUAL have formed an agreement, leveraging ACTUAL’s AI-driven capital planning technology to develop a comprehensive net-zero emissions strategy for The Pengerang Energy Complex (PEC). PEC is set to be one of the world’s largest and most competitive integrated condensate splitter and aromatics facilities. Having signed over $102B USD of off-take agreements with several blue-chip energy providers, including Equinor, Chevron, PTT, and Mitsui, PEC is anticipated to have higher margins and a materially lower environmental footprint than similar plants. PEC's outputs are strategically important for industries including textiles, bottling, housing, and pharmaceuticals. PEC is poised to set industry-leading benchmarks, achieving the lowest carbon footprint per ton of Paraxylene (PX) produced by any facility globally, thereby delivering best-in-class performance across many materials. The Agreement between NAE and ACTUAL focuses on building a scientifically and technologically credible transition plan leveraging ACTUAL’s AI-driven capital planning technology. The plan seeks to improve PEC's environmental performance further to move it towards becoming one of the first net-zero facilities globally. Decarbonizing complex plants like PEC requires a multi-layered approach. ACTUAL and NAE plan to iteratively investigate several strategies, such as the construction of green renewable power plants for facility operations; blue and green hydrogen production; native green feedstocks for the production of sustainable aviation fuel (SAF); carbon capture technologies such as the use of mineralization or algae; alternative sources for industrial heat such as geothermal, among many others. “ACTUAL’s technology was designed for exactly this kind of important effort — decarbonizing industries critical to our economy and resilience,” said Karthik Balakrishnan, co-founder of ACTUAL. “We are excited to collaborate with NAE to build scientifically valid capital plans that could set PEC on the path towards net zero.” “With our focus on investing in and operating high-margin, low-carbon facilities in Southeast Asia, engaging with new and innovative ways to improve our sustainability posture is critical,” said William I.Y. Byun, CEO of NAE. “This collaboration is exciting because of the potential to show a clear, articulate pathway towards net zero for one of the premier new facilities in the region.” About New ASEAN Energy: NAE focuses on the management and operations of low-carbon petrochemical plants in the ASEAN region. NAE is led by CEO William I.Y. Byun, a seasoned expert in infrastructure investing and renewable energy across the Asia climate sector, and CFO Mayank Vishnoi, who previously served as CEO of a listed holding company at SGX (Singapore) and worked on multiple fund-raising transactions in the infrastructure and renewable energy sectors across Southeast Asia. NAE’s board directors includes: Bobby Tudor, previously a partner with Goldman Sachs and the former Chairman and founder of Tudor, Pickering, Holt & Co., now a part of Perella Weinberg Partners Stephen Trauber, who previously served as the Vice Chairman & Global Head of Natural Resources & Clean Energy Transition for Citi Bank, Vice Chairman & Global Head of Energy for UBS, Managing Director and Head of Energy for Morgan Stanley and Vice President of Energy M&A Group for Credit Suisse First Boston Robert Turnham, former President, Director and founding partner of Goodrich Petroleum Corporation, a public exploration and production company for 26 years Neil Bush, Chairman of Atlas Renewable Inc, Co-Chairman of CIIC, Chairman of A&A Investments, Chairman of the George HW Bush Foundation for US China Relations, and Chairman of the Bush School of Government and Public Service Advisory Board Laique Rehman, founder and Chief Executive Officer of US Petrochemicals Inc About ACTUAL: Founded in 2018 by Rajesh Chandran, Karthik Balakrishnan, Ph.D., and Derek Lyons, Ph.D., ACTUAL builds the first-in-category AI-driven capital planning technology designed to help large enterprises globally build capital plans to meet their net-zero and UN-SDG aligned targets. ACTUAL’s platform enables leaders to build living capital plans that are always up to date, in compliance with evolving standards, and available for stakeholder inspection. ACTUAL’s platform has been recognized by Business Intelligence Group as a 2022 Sustainability Product of the Year, is a TIME Best Inventions 2022 winner and an honoree of Fast Company’s 2023 Innovation By Design Award. ACTUAL is backed by Energy Capital Ventures, Buckley Ventures, Hyper, Social Impact Capital, Wndrco, Sequoia Scout, Signalfire Scout, Craft Scout and Global Founders Capital. For more information, visit actualhq.com. About Pengerang Energy Complex: Pengerang Energy Complex (“PEC”) is set to be one of the largest and most competitive integrated condensate splitter and aromatics facilities in the world. PEC is located in the Pengerang Integrated Petroleum Complex (PIPC) in Johor, Malaysia, directly opposite Singapore. The resulting downstream products are used in a wide range of consumer products (textiles, bottles, housing, pharmaceuticals). The 6.5 million metric tonnes per annum (mmtpa) facility will in turn produce aromatics of 2.3 mmtpa, energy products output of 3.9 mmtpa and hydrogen output of 50,000 metric tonnes per annum (mtpa).The condensate splitter will produce heavy naphtha, a primary feedstock for the aromatics plant whereas the hydrogen produced is planned to be used to support development of downstream renewable fuels facilities in Johor. The US$5 billion project is estimated to generate an annual export turnover of US$5 billion for Malaysia. Involving fully automated processes, the greenfield PEC has been designed to optimize energy efficiency, minimize equipment size, and significantly reduce greenhouse gas emissions in line with International Financial Corporation’s (IFC) performance standards. Offering the latest technological advances, the world-class PEC facility will be one of the largest and most energy efficient integrated condensate splitter and aromatics facilities globally, strategically located to serve the regional Asian markets and satisfy forecast long-term sustained regional growth. ChemOne Group, a leading energy and petrochemicals project developer based in Singapore, is the master developer for the project. ChemOne’s successful track record over the last 40 years includes developing similar projects in Southeast Asia. Contacts Natalie Bartels VSC, on behalf of ACTUAL actual@vsc.co
-
Mobvista Achieves $1.05B in 2023 Revenue, Sees Significant Profit Increase
SINGAPORE--(BUSINESS WIRE)--Mobvista (1860.HK), a leading global marketing and advertising technology company, has today released its financial results for the twelve months ending December 31, 2023. Performance highlights: Group Revenue: Revenue increased 17.9% year-over-year (YoY) to the recorded high of $1.05 billion, and net revenue increased 26.2% YoY to $284 million. Group Profitability: A gross profit of $217 million, up 22.7% YoY, and an adjusted EBITDA of $105 million, up 191.3% YoY. Mintegral, a Mobvista subsidiary specializing in programmatic advertising, showcased exceptional performance. In 2023, Mintegral's revenue climbed to $980 million, up 18.8% YoY. Effective cost management and operational optimization markedly boosted business profitability. During the reporting period, Mobvista achieved notable improvements in cost efficiency due to advancements in its machine learning-based advertising systems. Additionally, by implementing multi-cloud scheduling, introducing various new computing technologies, and applying personalized computing power technology, Mobvista successfully met the goal of unit server cost reduction to 5% by the end of 2023. Regarding operational management in the fourth quarter of 2023, Mintegral achieved an impressive publisher retention rate of 94.7%. This period also saw a significant expansion in the supply-side business, as evidenced by a 21.8% increase in the number of apps partnering with Mintegral. Additionally, from 2022 to 2023, the retention rate of enterprise-level customers contributing over $100,000 in revenue, was 93.3%, with a dollar-based net expansion rate of 115.0%. Significant Breakthroughs in Mid-Core and Hardcore Game Revenue Mintegral has also actively seized opportunities in hybrid monetization, enhancing its targeting and bidding strategies, including return on ad spend (ROAS), to ensure the achievement of advertising goals. As a result, while maintaining its leading position in casual games, Mintegral further captured the mid-core and hardcore game market, which has a higher proportion of in-app purchases. Revenue from mid-core and hardcore games increased 66.3%, accounting for 29.1% of Mintegral's total revenue in 2023. The company conducted share buybacks exceeding HKD 100 million in 2023, and the buyback program is expected to continue, potentially further stabilizing investor expectations and boosting market confidence. For more detailed information on Mobvista's financial highlights, please refer to the 2023 Financial Report. About Mobvista Mobvista delivers the technology that drives app businesses towards global growth. Our suite of software is powered by advanced machine learning and supports every phase of the user journey. We provide meaningful user engagement, make user acquisition efficient, and maximize your app's revenue potential. For more information, please visit www.mobvista.com. Contacts Media Relations marketing@mobvista.com
-
ICP DAS-BMP Secures Pivotal TPU Deals with Medical Materials Leaders in U.S. and Japan, Boosts Product Reliability
HSINCHU, March 19, 2024 /PRNewswire/ -- ICP DAS-BMP dazzled at the prestigious MD&M West Show, where its high-quality medical-grade thermoplastic polyurethane (TPU) garnered orders from top manufacturers in U.S. and Japan. Concurrently, part of the company's TPU products passed the ISO10993-6 test for local effects after 90-day implantation, positioning them as ideal materials for producing indwelling medical devices intended for use over 30 days. ICP DAS-BMP Secures Pivotal TPU Deals with Medical Materials Leaders in U.S. and Japan, Boosts Product Reliability ICP DAS-BMP, Asia's first medical-grade TPU supplier, produces three main series of products: Alithane™ (ALP series), Durathane™ (ALC series), and Arothane™ (ARP series). The company is set to launch a new Durathane™ (ARC series), known for its exceptional biostability. All the TPU series are available in different hardness levels, colors, and concentrations of radiopaque fillers (Tungsten/Barium Sulfate). These materials are widely utilized in manufacturing cardiovascular, urological, and gastrointestinal devices, as well as medical and electromedical consumables. ICP DAS-BMP's Arothane™ ARP-B20 (20% Barium Sulfate) and Durathane™ ALC-B40 (40% Barium Sulfate) passed the ISO10993-6 90-day implantation test. This qualifies them for long-term invasive or implantable medical applications such as peripherally inserted central catheters (PICC) and port-a-cath. The company plans to conduct long-term implantation tests for other specifications of TPU products based on customer demand, while advancing research and development to uphold TPU product quality. ICP DAS-BMP Medical Grade TPU Biocompatibility and Other Testing Medical-grade TPU differs from other plastics by emitting minimal VOCs during manufacturing and having low wastewater discharge, making it extremely environmentally friendly. It contains no plasticizers or heavy metals, ensuring excellent biocompatibility and blood compatibility, and enhancing ESG sustainability. ICP DAS-BMP aims to offer safer, stable, and eco-friendly medical-grade TPU, collaborating with global medical device manufacturers to create long-term benefits and value. Meet the company's experts at: CMEF (ICMD) 2024 (April 11-14) Booth Hall 8.1, M44, M46 NECC (Shanghai), China Medtec Japan 2024 (April 17-19) Booth 2022 Tokyo Big Sight East 2~3 Hall, Japan About ICP DAS-BMP ICP DAS-BMP, a Taiwan-based TPU manufacturer and supplier certified with ISO 13485, operates specialized laboratories dedicated to quality management. Drawing upon three decades of industrial automation expertise from its parent company ICP DAS, ICP DAS-BMP has implemented smart factory practices to enhance product quality and expedite delivery times. Additionally, the company provides responsive after-sales support and offers flexible solutions for small order quantities. For more information, please visit: https://bmp.icpdas.com/ For TPU products and inquiries, contact: sales_bmp@icpdas.com